Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Insurance coverage decisions directly determine whether people with Alzheimer’s disease can access the medications that might slow cognitive decline. When an insurance company decides not to cover a drug, delays approval through prior authorization, or places a medication on a high-tier formulary with prohibitive copays, many patients simply don’t take it—not because they don’t want to, but because they can’t afford it or can’t wait for approval. For example, a 68-year-old woman diagnosed with early Alzheimer’s might be prescribed lecanemab, a monoclonal antibody that has shown efficacy in slowing cognitive decline, but if her insurance plan doesn’t cover it or requires a $500 monthly copay, she may never start the treatment, leaving the medication prescribed but unused on a pharmacy shelf.
The insurance system creates multiple decision points that affect drug use: whether a medication is covered at all, what category (tier) it’s placed in, whether prior authorization is required, what the patient’s out-of-pocket costs will be, and whether the insurance company will pay for ongoing treatment or will terminate coverage after a certain period. These decisions are made by insurance companies (Medicare Advantage plans, Medicaid programs, private insurers), pharmacy benefit managers (PBMs), and sometimes the employers who sponsor health plans. The result is a patchwork of coverage that means identical patients with identical diagnoses may have vastly different access to the same drugs.
Table of Contents
- How Insurance Formularies Control Which Alzheimer’s Drugs You Can Access
- Prior Authorization Delays and Denials Block Access Even When Insurance Should Cover
- Cost-Sharing Burden Means Patients Choose Not to Fill Prescriptions
- Appeals and Step Therapy: Fighting Your Insurance Company Takes Time and Persistence
- Medicare Advantage vs. Original Medicare vs. Private Insurance Create Different Drug Access
- Manufacturer Patient Assistance Programs Offer a Workaround for Some
- When Insurance Decisions Trump Medical Decisions
- Frequently Asked Questions
How Insurance Formularies Control Which Alzheimer’s Drugs You Can Access
Formularies are the lists of medications that an insurance plan agrees to cover. When an Alzheimer’s drug is on the formulary, it’s covered; when it’s not, the patient pays the full price or the drug goes unused. Most major medicare Advantage plans do cover standard Alzheimer’s medications like donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), but newer drugs like lecanemab (Leqembi) and donanemab (Kisunla)—which are monoclonal antibodies that target amyloid plaques in the brain—are often excluded or heavily restricted. The reason is cost. Lecanemab costs approximately $26,500 per year, and donanemab is similarly expensive.
When insurance companies decide not to add a new drug to their formulary, they’re making a coverage decision based on cost-benefit analysis. A patient whose doctor prescribes lecanemab but finds it’s not on their Medicare Advantage plan’s formulary has a few options: pay the full $26,500 out of pocket, appeal the insurance decision, switch insurance plans (if switching is available during open enrollment), or not take the drug at all. Many choose the last option, especially on fixed incomes. Even when a drug is on the formulary, it may be placed on a higher tier, which means higher copays. Tier 1 drugs typically cost $5–15 per prescription, while tier 3 or specialty tier drugs can cost $50–$300 per prescription or more. A patient might be willing to take a generic donepezil at a tier 1 copay but unable to afford a specialty tier medication, so their doctor’s prescription becomes irrelevant to their actual medication use.
Prior Authorization Delays and Denials Block Access Even When Insurance Should Cover
Prior authorization is a process where the prescribing doctor must get approval from the insurance company before the patient fills the prescription. The insurance company reviews the patient’s medical history and the medication’s indication to determine whether it’s medically necessary. In theory, prior authorization prevents unnecessary prescriptions. In practice, it delays treatment and creates barriers that some patients never get past. For a patient with early-stage Alzheimer’s, a few weeks of delay can matter. Lecanemab has shown the most benefit when started early in cognitive decline, when the disease is still causing mild cognitive impairment. If an insurance company’s prior authorization process takes 3–4 weeks, and then the authorization is denied, the patient has lost valuable time.
They may then appeal the denial, which takes another 2–4 weeks, and by the time approval comes (if it comes), the disease may have progressed. Some patients give up during the process and never start the drug. Insurance denials are not uncommon. A patient might be denied lecanemab because the insurance company’s medical reviewer determines that their cognitive decline isn’t severe enough or isn’t mild enough to meet the criteria the insurance company has set (which may differ from the drug’s FDA-approved indication). An appeal can reverse the denial, but appeals require the patient, family member, or doctor to navigate a formal process, gather additional documentation, and wait weeks or months. Not everyone has the time, energy, or knowledge to appeal successfully. The warning here is clear: even if a drug is technically on your insurance plan’s formulary, prior authorization can prevent you from accessing it.
Cost-Sharing Burden Means Patients Choose Not to Fill Prescriptions
The copay, deductible, and coinsurance that patients pay out of pocket have a direct effect on whether they fill prescriptions and stay on medication. Studies of medication adherence show that patients are more likely to skip doses or stop taking medications entirely when out-of-pocket costs are high. For Alzheimer’s disease, where the goal is to slow decline and maintain cognitive function over months or years, stopping medication early means losing the potential benefit. Consider a specific example: a 72-year-old man is prescribed donepezil for mild cognitive impairment, and his Medicare Advantage plan places it on tier 2, with a $35 copay per 30-day supply. Over a year, that’s $420 out of pocket.
For many retirees on fixed incomes, this is manageable. But if his insurance plan later adds a newer medication like lecanemab as an alternative, and it’s placed on the specialty tier with a $200 monthly copay, he faces a decision: stay on the donepezil he can afford, or switch to lecanemab and cut back on groceries or other medical care. Insurance companies have noted that higher cost-sharing leads to lower medication initiation rates, particularly among Medicare beneficiaries. The Inflation Reduction Act placed a $35 monthly cap on insulin copays for Medicare beneficiaries, but no similar cap exists for Alzheimer’s drugs. This means cost-sharing for Alzheimer’s medications can remain a significant barrier, especially for newer, more expensive drugs.
Appeals and Step Therapy: Fighting Your Insurance Company Takes Time and Persistence
When an insurance company denies coverage or requires prior authorization, the patient or doctor can appeal. But appeals processes vary by insurance company and by state, and most take 30–60 days. Some insurance companies also use “step therapy,” which means a patient must fail on a cheaper drug first before the insurance company will cover a more expensive one. If a doctor prescribes lecanemab as a first-line treatment because the patient hasn’t tried other drugs yet, the insurance company may deny it and require the patient to first try donepezil or galantamine and fail (meaning their cognition continues to decline despite the medication) before lecanemab will be covered. The problem with step therapy for Alzheimer’s disease is that time matters more than it does for many other conditions. If a drug delays decline by, say, 30% in early stages, starting that drug one year later means the disease has progressed further and the patient may no longer be eligible for the medication.
Lecanemab, for example, is indicated for patients with mild cognitive impairment or mild dementia; it’s not recommended for more advanced stages. If step therapy delays a patient’s start date by a year, they may have progressed beyond the stage where lecanemab is appropriate, even if they eventually win their appeal. Appeals also require someone to advocate for the patient. This might be the patient, a family member, or the doctor’s office. Not all patients have a family member who can help, and not all doctors have the staff time to file insurance appeals. Patients without strong advocates are less likely to successfully appeal denials, which means they’re less likely to access the medication.
Medicare Advantage vs. Original Medicare vs. Private Insurance Create Different Drug Access
Not all insurance plans make the same coverage decisions. Medicare Advantage plans, which are private insurance plans that Medicare beneficiaries can choose as an alternative to original Medicare, each create their own drug formularies. Plan A might cover lecanemab with a $100 copay, Plan B might deny it entirely, and Plan C might cover it but require prior authorization for every prescription renewal. Original Medicare (Parts A and B) doesn’t cover outpatient prescription drugs, but beneficiaries can add a Part D drug plan, which also creates a different set of formulary decisions. A beneficiary with Medicare + a Part D plan might have better coverage for Alzheimer’s drugs than a beneficiary in a Medicare Advantage plan that doesn’t cover them well, or vice versa.
The coverage is not standardized, so patients must carefully review plan details during open enrollment to understand what Alzheimer’s drugs are covered and at what cost. Private insurance through employers or the individual market creates yet another set of variations. Some employer plans are generous with Alzheimer’s drug coverage because the employer decides cost is less important than supporting employees and their families. Others are restrictive to control costs. There is no national standard, no baseline of coverage that all plans must meet for Alzheimer’s drugs. This fragmentation means that insurance decisions about coverage are a major determinant of drug use: a patient in a generous plan uses the medication, while an identical patient in a restrictive plan does not.
Manufacturer Patient Assistance Programs Offer a Workaround for Some
When insurance doesn’t cover a drug, the manufacturer often provides it for free or at a reduced cost through a patient assistance program (PAP). Lecanemab’s manufacturer, Eisai, offers a patient assistance program that can provide the drug at no cost for uninsured or underinsured patients who meet income requirements. Donanemab’s manufacturer does the same. These programs exist because even manufacturers recognize that insurance decisions create access barriers.
However, patient assistance programs have limitations. They require patients to complete applications, provide income documentation, and often require the patient to demonstrate that they’ve tried other treatments first or that they’ve been denied insurance coverage. The process takes time, and not all patients know these programs exist or have the ability to navigate the application. Additionally, a patient on a patient assistance program who later gains insurance coverage must transition off the program to the insurance plan’s coverage, which may interrupt their treatment temporarily.
When Insurance Decisions Trump Medical Decisions
The most sobering aspect of insurance’s role in Alzheimer’s drug use is that insurance coverage decisions, not medical need, often determine whether patients receive treatment. A patient with a clear diagnosis of mild cognitive impairment, who meets all medical criteria for lecanemab, and whose doctor believes the drug will benefit them, may not receive it because their insurance plan doesn’t cover it. Another patient with the same diagnosis, in the same age group, with the same disease stage, in a neighboring state or with a different insurance plan, will receive it and potentially have their decline slowed.
This creates a two-tiered system of care where medical outcomes depend partly on insurance luck. The insurance decision—made by a company employee reviewing paperwork—can be as important as the doctor’s decision about which drug to prescribe. For families caring for someone with Alzheimer’s, understanding that insurance decisions directly affect drug access is critical to knowing how to advocate for their loved one.
- —
Frequently Asked Questions
Does Medicare cover lecanemab?
Medicare coverage for lecanemab varies by plan. Original Medicare Part D plans may cover it, but policies differ by plan. Many Medicare Advantage plans have restricted or excluded lecanemab from their formularies, though this is changing as the drug ages. Always check your specific plan’s formulary to confirm coverage.
What is prior authorization and why does it matter for Alzheimer’s drugs?
Prior authorization is a process where your doctor must get permission from your insurance company before you fill a prescription. Insurance companies use it to prevent unnecessary medications and control costs, but it can delay treatment by weeks or months. For early-stage Alzheimer’s disease, this delay can mean the disease progresses before you start medication that works best in early stages.
How much do Alzheimer’s medications cost without insurance?
Older medications like generic donepezil cost $10–50 per month. Newer monoclonal antibodies like lecanemab cost approximately $26,500 per year ($2,200 per month). Donanemab is similarly expensive. Most patients cannot afford these prices out of pocket.
What can I do if my insurance company denies coverage for an Alzheimer’s drug?
You can appeal the denial, often with help from your doctor’s office. The appeal process typically takes 30–60 days. If the appeal is also denied, you can request a second opinion from an independent medical reviewer. You can also check if the drug manufacturer offers a patient assistance program that provides it free or at reduced cost to qualified patients.
Can I switch insurance plans to get coverage for a drug my plan won’t cover?
You can switch insurance plans during open enrollment periods (usually November–December for Medicare, depending on plan type). However, switching plans affects all your coverage, not just the one drug. Carefully compare coverage for all your medications and healthcare needs before making a switch.
Does the Inflation Reduction Act help with Alzheimer’s drug costs?
The Inflation Reduction Act capped insulin copays at $35 monthly for Medicare beneficiaries but did not extend similar caps to Alzheimer’s medications. Alzheimer’s drug costs remain uncapped and can be prohibitively high, particularly for specialty tier medications. —
